ACTBL2 and ovarian carcinoma: Further studies evaluating the targeted antiproliferative use of Etomoxir are necessary to precisely analyze its impact on NFAT5 and ACTBL2 expression in vitro and in vivo with special regard to consecutively altered cellular functions in epithelial ovarian cancer.